跳至主要内容
临床试验/CTRI/2009/091/000702
CTRI/2009/091/000702已完成2 期

A clinical study of a herbal formulation 'Diabeat' as an adjuvant drug for the control of type 2 diabetes mellitus

Hamdard National Foundation New DElhi1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2011年10月23日最近更新:

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
50
试验地点
1
主要终点
Mean HbA1C 6.5%

研究概览

简要总结

This study is a randomized, double blind parallel group, trial comparing the safety and efficacy of 'Diabeat'(1gram twice daily) plus standard drug(Metformin SR-500 mgtwice daily)with placebo (1gram twice daily)plus standard drug(Metformin SR-500mg twice daily)in 100 patients of Type 2 diabetes mellitus that will be conducted in Majeedia Hospital,New Delhi. The primary outcome measures will be To achieve a good glycemic control (FPG-80-120 mg/dl; PPG-80-140 mg/dl,Time point:4,8,12 weeks . The secondary outcome will be Mean HbA1C< 6.5%, Time point: 3 months

研究设计

研究类型
Interventional
分配方式
Random Number Table
盲法
Participant and Outcome Assessor Blinded

入排标准

年龄范围
30.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • Patients of type-2 diabetes mellitus, age 30-60 years taking Metformin for more than 3 months with uncontrolled hyperglycaemia i.e.HbA1C between 7% to 9% and Body Mass Index (BMI) between 25-29.9 kg/m
  • Patients who are able and willing to follow anti-diabetic therapy under a stable life style and diabetic diet.
  • 3.Patients who are willing and able to understand and follow the protocol and provide informed consent.

排除标准

  • 1.History of treatment with any insulin 2.Diabetes mellitus with complications 3.Pregnant or Lactating women 4.Women of childbearing potential who do not take adequate contraceptive protection.
  • 5.History of hypersensitivity to the Metformin or to drug with similar chemical structure.
  • 6.History of any severe systemic disease.
  • 7.Patients with uncontrolled hypertension.
  • 8.History of drug or alcohol abuse.

结局指标

主要结局

Mean HbA1C 6.5%

时间窗: 12 weeks

次要结局

  • To achieve a good glycemic control (FPG-80-120 mg/dl; PPG-80-140 mg/dl)(4,8,12 week)

研究者

发起方
Hamdard National Foundation New DElhi
申办方类型
Pharmaceutical industry-Indian

研究点 (1)

Loading locations...

相似试验